Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder that is described by multiple factors linked with the progression of the disease. The currently approved drugs in the market are not capable of curing AD; instead, they merely provide symptomatic relief. Development of multi-target directed ligands (MTDLs) is an emerging strategy for improving the quality of the treatment against complex diseases like AD. Polypharmacology is a branch of pharmaceutical sciences that deals with the MTDL development. In this mini-review, we have summarized and discussed different strategies that are reported in the literature to design MTDLs for AD. Further, we have discussed the role of different in silico techniques and online resources in computer-aided drug discovery (CADD), for designing or identifying MTDLs against AD.
Keywords: Alzheimer's disease, CADD, polypharmacology, multi-target directed ligands.
Graphical Abstract
Current Drug Targets
Title:CADD Modeling of Multi-Target Drugs Against Alzheimer's Disease
Volume: 18 Issue: 5
Author(s): Pravin Ambure and Kunal Roy
Affiliation:
Keywords: Alzheimer's disease, CADD, polypharmacology, multi-target directed ligands.
Abstract: Alzheimer’s disease (AD) is a neurodegenerative disorder that is described by multiple factors linked with the progression of the disease. The currently approved drugs in the market are not capable of curing AD; instead, they merely provide symptomatic relief. Development of multi-target directed ligands (MTDLs) is an emerging strategy for improving the quality of the treatment against complex diseases like AD. Polypharmacology is a branch of pharmaceutical sciences that deals with the MTDL development. In this mini-review, we have summarized and discussed different strategies that are reported in the literature to design MTDLs for AD. Further, we have discussed the role of different in silico techniques and online resources in computer-aided drug discovery (CADD), for designing or identifying MTDLs against AD.
Export Options
About this article
Cite this article as:
Ambure Pravin and Roy Kunal, CADD Modeling of Multi-Target Drugs Against Alzheimer's Disease, Current Drug Targets 2017; 18 (5) . https://dx.doi.org/10.2174/1389450116666150907104855
DOI https://dx.doi.org/10.2174/1389450116666150907104855 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ameliorative Effect of Phosphodiesterase-5 Inhibitor in Rat Model of Vascular Dementia
Current Neurovascular Research Cardiovascular Adverse Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neurofibrillary Tangles and Senile Plaques in Alzheimers Brains are Associated with Reduced Capillary Expression of Vascular Endothelial Growth Factor and Endothelial Nitric Oxide Synthase
Current Neurovascular Research Adiposity and Alzheimers Disease
Current Alzheimer Research Editorial [Hot Topic: Cardiovascular Disease: Focus on Dyslipidemia (Executive Guest Editor: I. Gouni-Berthold)]
Current Pharmaceutical Design The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H<sub>3</sub> Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation
Current Alzheimer Research Serotonergic and Cholinergic Strategies as Potential Targets for the Treatment of Schizophrenia
Current Pharmaceutical Design Nanowired Drug Delivery to Enhance Neuroprotection in Spinal Cord Injury
CNS & Neurological Disorders - Drug Targets Impact of Traditional Therapies and Biologics on Cardiovascular Diseases in Rheumatoid Arthritis
Current Vascular Pharmacology Dehydroevodiamine•HCl Protects Against Memory Impairment and Cerebral Amyloid-β Production in Tg2576 Mice by Acting as a β-Secretase Inhibitor
CNS & Neurological Disorders - Drug Targets Bone Loss and Osteoporosis are Associated with Conversion from Mild Cognitive Impairment to Alzheimer’s Disease
Current Alzheimer Research Mediterranean Diet and Low-grade Subclinical Inflammation: The Moli-sani Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Assessing Activation States in Microglia
CNS & Neurological Disorders - Drug Targets Exploring N<sup>1</sup>-p-Fluorobenzyl-Cymserine as an Inhibitor of 5-Lipoxygenase as a Candidate for Type 2 Diabetes and Neurodegenerative Disorder Treatment
CNS & Neurological Disorders - Drug Targets Unexpected Effects of Acetylcholine Precursors on Pilocarpine Seizure- Induced Neuronal Death
Current Neuropharmacology Non-Analgesic Effects of Opioids: The Cognitive Effects of Opioids in Chronic Pain of Malignant and Non-Malignant Origin. An Update.
Current Pharmaceutical Design The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews Editorial [Hot topic: Alzheimers Disease Drug Discovery: Aβ and Beyond (Guest Editors: D.W. Shineman and H.M. Fillit)]
Current Alzheimer Research The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease
CNS & Neurological Disorders - Drug Targets